新生児の播種性血管内凝固に対するメシル酸ナファモスタット（Ｆｕｔｈａｎ）の治療効果―メシル酸ガベキセート（ＦＯＹ）との比較―

DOI 被引用文献1件 参考文献11件
  • 塙坂 八重
    奈良県立医科大学附属病院周産期医療センター新生児集中治療部門
  • 高橋 幸博
    奈良県立医科大学附属病院周産期医療センター新生児集中治療部門
  • 川口 千晴
    奈良県立医科大学附属病院周産期医療センター新生児集中治療部門
  • 森川 肇
    奈良県立医科大学附属病院周産期医療センター新生児集中治療部門
  • 安原 肇
    奈良県立医科大学小児科
  • 吉田 幸一
    奈良県立医科大学小児科
  • 吉岡 章
    奈良県立医科大学小児科

書誌事項

タイトル別名
  • Clinical Effect of Nafamostat Mesilate for Disseminated Intravascular Coagulation of Neonate - The Comparison with Gabexate Mesilate -
  • The Comparison with Gabexate Mesilate
  • メシル酸ガベキセート (FOY<SUP>®</SUP>) との比較

この論文をさがす

抄録

The clinical efficacy of the protease inhibitor, nafamostat mesilate (Futhan®) in treating sick newborns with disseminated intravascular coagulation (DIC) was compared with that of another protease inhibitor, gabexate mesilate (FOY®). Records were reviewed for 24 DIC low-birth-weight infants and high-risk newborns, including those who had undergone surgery, admitted to our division of neonatal intensive care unit between January 1993 and December 2001. All patients displayed DIC or probable DIC until day 28, and a neonatal DIC score as proposed by Shirahata of three or more points. Twelve patients were treated using Futhan® and the other twelve were treated using FOY®. Both protease inhibitors were effective and significantly improved DIC scores, particularly for platelets and FDP components. However, one patient in the Futhan® group developed hyperkalemia without renal failure. Futhan® is useful for treating neonatal DIC patients, but serum potassium levels must be closely monitored during Futhan® administration.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (11)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ